3Q Revenues: $5.9 billion (-2%)
3Q Earnings: $1.1 billion (-28%)
YTD Revenues: $17.8 billion (-1%)
YTD Earnings: $6.2 billion (+26%)
Comments: Januvia sales were $379 million in the quarter (+105%). Sales of Isentress were $107 million. Worldwide sales of Singulair were $1.0 billion (+1%). Cozaar and Hyzaar sales were $888 million (+9%). Combined worldwide sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough joint venture, were $1.1 billion in the quarter (-15%). Worldwide sales of the Gardasil were $401 million (-4%). R&D expenses were $1.2 billion in the quarter (-19%). Restructuring costs, primarily related to employee separation costs associated with the company's global restructuring programs, were $757 million in the quarter and $49 million in 3Q07.